Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 297 of the 299 references it cites were found in a registry or an index; 98 of the 267 sources its claims cite were checked for support.

Hormonal treatments for endometriosis: The endocrine background

Open access
Vannuccini, Silvia, Clemenza, Sara, Rossi, Margherita, Petraglia, Felice · 2022 · Reviews in Endocrine and Metabolic Disorders

Abstract

Endometriosis is a benign uterine disorder characterized by menstrual pain and infertility, deeply affecting women's health. It is a chronic disease and requires a long term management. Hormonal drugs are currently the most used for the medical treatment and are based on the endocrine pathogenetic aspects. Estrogen-dependency and progesterone-resistance are the key events which cause the ectopic implantation of endometrial cells, decreasing apoptosis and increasing oxidative stress, inflammation and neuroangiogenesis. Endometriotic cells express AMH, TGF-related growth factors (inhibin, activin, follistatin) CRH and stress related peptides. Endocrine and inflammatory changes explain pain and infertility, and the systemic comorbidities described in these patients, such as autoimmune (thyroiditis, arthritis, allergies), inflammatory (gastrointestinal/urinary diseases) and mental health disorders.The hormonal treatment of endometriosis aims to block of menstruation through an inhibition of hypothalamus-pituitary-ovary axis or by causing a pseudodecidualization with consequent amenorrhea, impairing the progression of endometriotic implants. GnRH agonists and antagonists are effective on endometriosis by acting on pituitary-ovarian function. Progestins are mostly used for long term treatments (dienogest, NETA, MPA) and act on multiple sites of action. Combined oral contraceptives are also used for reducing endometriosis symptoms by inhibiting ovarian function. Clinical trials are currently going on selective progesterone receptor modulators, selective estrogen receptor modulators and aromatase inhibitors. Nowadays, all these hormonal drugs are considered the first-line treatment for women with endometriosis to improve their symptoms, to postpone surgery or to prevent post-surgical disease recurrence. This review aims to provide a comprehensive state-of-the-art on the current and future hormonal treatments for endometriosis, exploring the endocrine background of the disease.

Overview

CoChat Summary

## TL;DR

This review explains how estrogen dependency, progesterone resistance, and broader endocrine/inflammatory changes shape endometriosis and motivate hormonal treatment. It concludes that hormonal therapies are the cornerstone of management for symptom control, delaying surgery, and reducing postoperative recurrence, though they do not cure the disease.

## Key findings

  • Endometriosis is described as a chronic disease affecting reproductive-age women, with prevalence reported as 2–10% in women of reproductive age, 30–50% among infertile women, and 5–21% among women with severe pelvic pain.
  • The paper identifies estrogen-dependency and progesterone-resistance as the key endocrine events driving ectopic implantation, reduced apoptosis, increased oxidative stress, inflammation, and neuroangiogenesis.
  • GnRH agonists improved endometriosis-associated pain; a meta-analysis of 41 trials found them more effective than placebo and as effective as other progestins for pain relief. Treatment for 3–6 months before ART may increase the odds of clinical pregnancy by fourfold.
  • Elagolix (a GnRH antagonist) reduced dysmenorrhea and non-menstrual pelvic pain in two multicenter, double-blind, randomized phase 3 trials over 6 months; extension studies reported benefit over 12 months with improved QoL and reduced analgesic use.
  • For postoperative prevention, the LNG-IUS and dienogest lowered recurrence: in one study, recurrence at 6 and 12 months was 3.8% and 9.7% in treatment groups versus 32.5% in controls.
  • The review notes that progestins are first-choice therapy per ESHRE guidelines and that about two thirds of patients are satisfied with progestins for symptomatic endometriosis.

## Methods

  • Narrative review of the endocrine background of endometriosis and the hormonal therapies used or under development.
  • Draws on prior studies, including trials, cohort studies, systematic reviews, meta-analyses, and guideline statements, rather than reporting a new primary dataset.
  • Synthesizes evidence across endocrine mechanisms, clinical symptoms, comorbidities, and treatments such as progestins, GnRH agonists/antagonists, COCs, SPRMs, SERMs, and aromatase inhibitors.

## Limitations

  • Not stated in the paper. The paper does not describe a formal search strategy, inclusion/exclusion criteria, or systematic review methods.
  • Not stated in the paper. It does not quantify the strength of evidence across all interventions in a standardized way, beyond citing selected studies and guidelines.
  • Evident from the text: as a review, it is dependent on previously published studies and some therapeutic areas are described as having limited data or insufficient data to permit firm conclusions (for example, SPRMs).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11154-021-09666-w

Cites

297 of 297 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Estrogen receptors activity and local estrogens production in endometriosis. 17β-HSD, 17β-hydroxysteroid dehydrogenase. E2, estradiol. E3, estrone
Fig. 1 Estrogen receptors activity and local estrogens production in endometriosis. 17β-HSD, 17β-hydroxysteroid dehydrogenase. E2, estradiol. E3, estroneCC BY · PubMed Central
Fig. 2 The mechanisms of progesterone-resistance in endometriosis
Fig. 2 The mechanisms of progesterone-resistance in endometriosisCC BY · PubMed Central
Fig. 3 Hypothalamus–pituitary–adrenal (HPA) axis and stress hormones in endometriosis
Fig. 3 Hypothalamus–pituitary–adrenal (HPA) axis and stress hormones in endometriosisCC BY · PubMed Central
Fig. 4 Hormonal targets of currently used drugs for endometriosis
Fig. 4 Hormonal targets of currently used drugs for endometriosisCC BY · PubMed Central

Verification

Claims the paper makes

76 Valid · 8 Not valid · 110 Not checked · 20 Own results and interpretations

107 more claims · 35 with their cited sources checked

Create a free account to see all 214 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 94
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 299 references

Research works printed but not linked: 8

  1. Bulun SE, Monsavais D, Pavone ME, et al. Role of estrogen receptor-beta in endometriosis. Semin Reprod Med. 2012;30(1):39–45. https://doi.org/10.1055/s-0031-1299596. · DOI · Paper page
  2. Reis FM, Petraglia F, Taylor RN. Endometriosis: Hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013. https://doi.org/10.1093/humupd/dmt010. · DOI · Paper page
  3. Han SJ, Jung SY, Wu SP, et al. Estrogen Receptor β Modulates Apoptosis Complexes and the Inflammasome to Drive the Pathogenesis of Endometriosis. Cell. 2015. https://doi.org/10.1016/j.cell.2015.10.034. · DOI · Paper page
  4. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012. https://doi.org/10.1016/j.fertnstert.2012.06.029. · DOI · Paper page
  5. Barra F, Grandi G, Tantari M, Scala C, Facchinetti F, Ferrero S. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin Biol Ther. 2019;19(4):343–60. https://doi.org/10.1080/14712598.2019.1581761. · DOI · Paper page
  6. Dunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: Management of women with endometriosis. Hum Reprod. 2014. https://doi.org/10.1093/humrep/det457. · DOI · Paper page
  7. Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA. Dienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017. https://doi.org/10.1016/j.ejogrb.2017.02.015. · DOI · Paper page
  8. Techatraisak K, Hestiantoro A, Ruey S, et al. Effectiveness of dienogest in improving quality of life in Asian women with endometriosis (ENVISIOeN): Interim results from a prospective cohort study under real-life clinical practice. BMC Womens Health. 2019. https://doi.org/10.1186/s12905-019-0758-6. · DOI · Paper page

Cited by

See all 336

Metadata

Authors
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F.
Affiliations
Azienda Ospedaliero-Universitaria Careggi (IT)
Corresponding author
Petraglia, Felice
Venue
Reviews in Endocrine and Metabolic Disorders
Published
2021-08-17
Volume
23
Issue
3
Pages
333-355
ISSN
  • 1389-9155 (ISSN-L)
  • 1573-2606
OpenAlex
W3194419458
Cited by
336
References
299
Citations by year
2026: 80 · 2025: 96 · 2024: 75 · 2023: 56 · 2022: 27 · 2021: 2
FWCI
6.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Reviews in Endocrine and Metabolic Disorders (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion, other-oa)
Funders
Università degli Studi di Firenze
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
Keywords
endometriosis, hormone therapy, estrogen dependence, progesterone resistance, GnRH agonist, GnRH antagonist, progestins, combined oral contraceptives, selective progesterone receptor modulators, selective estrogen receptor modulators, aromatase inhibitors, hypothalamic-pituitary-ovarian axis, anti-Müllerian hormone, corticotropin-releasing factor, oxidative stress, inflammation, infertility, dysmenorrhea, comorbidities, recurrence
MeSH terms
Endometriosis, Endometrium, Female, Humans, Infertility, Uterine Diseases, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hormonal treatments for endometriosis: The endocrine background. https://app.cochat.ai/papers/10.1007/s11154-021-09666-w
The paper
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022). Hormonal treatments for endometriosis: The endocrine background. Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-021-09666-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.